AU7979491A - Intracellular delivery of biologically active substances by means of self-assembling lipid complexes - Google Patents

Intracellular delivery of biologically active substances by means of self-assembling lipid complexes

Info

Publication number
AU7979491A
AU7979491A AU79794/91A AU7979491A AU7979491A AU 7979491 A AU7979491 A AU 7979491A AU 79794/91 A AU79794/91 A AU 79794/91A AU 7979491 A AU7979491 A AU 7979491A AU 7979491 A AU7979491 A AU 7979491A
Authority
AU
Australia
Prior art keywords
self
means
biologically active
active substances
intracellular delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU79794/91A
Inventor
Philip L. Felgner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vical Inc
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US51929190A priority Critical
Priority to US519291 priority
Application filed by Vical Inc filed Critical Vical Inc
Publication of AU7979491A publication Critical patent/AU7979491A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
AU79794/91A 1990-05-03 1991-04-29 Intracellular delivery of biologically active substances by means of self-assembling lipid complexes Abandoned AU7979491A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US51929190A true 1990-05-03 1990-05-03
US519291 1990-05-03

Publications (1)

Publication Number Publication Date
AU7979491A true AU7979491A (en) 1991-11-27

Family

ID=24067677

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79794/91A Abandoned AU7979491A (en) 1990-05-03 1991-04-29 Intracellular delivery of biologically active substances by means of self-assembling lipid complexes

Country Status (2)

Country Link
AU (1) AU7979491A (en)
WO (1) WO1991017424A1 (en)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430968B1 (en) * 1988-05-02 1996-11-20 PHANOS TECHNOLOGIES, Inc. Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
WO1994027435A1 (en) 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6312719B1 (en) 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6773719B2 (en) 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
CN1136920C (en) 1995-02-28 2004-02-04 加利福尼亚大学董事会 Gene transfer-mediated angiogenesis therapy
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
EP0863749A2 (en) 1995-11-30 1998-09-16 Vical Incorporated Complex cationic lipids
ES2305157T3 (en) * 1996-09-13 2008-11-01 Lipoxen Technologies Limited Liposomes.
NZ334709A (en) 1996-10-01 2001-06-29 Univ Technology Corp Detection of hTRT activity or expression and use in the treatment of cancer
US5746223A (en) 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
FR2766705B1 (en) * 1997-07-30 2001-05-25 Biovector Therapeutics particulate complex of overall neutral charge or negative form of a cationic or neutral vesicle and an anionic biologically active substance, their preparation and their use
FR2766706B1 (en) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa stable particulate complexes of overall neutral charge or negative multilamellar structure of compounds with at least one globally anionic biologically active substance and a cationic component, their preparation and use
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
DE69900841T2 (en) 1998-01-23 2002-10-02 Newbiotics Inc By enzyme catalysis obtained therapeutic substances.
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
EP1075519B1 (en) 1998-05-06 2005-11-09 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Inhibitors of nf-kb activation
EP2298728A1 (en) 1998-11-12 2011-03-23 Life Technologies Corporation Transfection reagents
US6627215B1 (en) 1998-12-30 2003-09-30 Oligos Etc. Inc. Devices for improved wound management
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US7868162B2 (en) 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
AT442839T (en) 1999-04-01 2009-10-15 Hana Biosciences Inc Compositions and methods for treating lymphoma
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US7244450B2 (en) 1999-04-01 2007-07-17 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US20030083273A1 (en) * 1999-04-20 2003-05-01 Tod M. Woolf Antisense oligomers
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
EP1200130A2 (en) 1999-07-22 2002-05-02 Newbiotics, Inc. Methods for treating therapy-resistant tumors
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
EP1359921A4 (en) 2001-01-19 2006-09-06 Newbiotics Inc Methods to treat autoimmune and inflammatory conditions
ES2269736T3 (en) 2001-06-22 2007-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Protection against hepatitis mediated abin.
US20030207834A1 (en) 2001-07-10 2003-11-06 Dale Roderic M.K. Oligonucleotide-containing pharmacological compositions and their use
WO2003027247A2 (en) 2001-09-24 2003-04-03 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
WO2003057728A1 (en) 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
DE10322123A1 (en) * 2003-05-12 2004-12-16 Novosom Ag Stable anionic liposome depot system for prolonged release of protein or peptide drugs, e.g. insulin, comprising phosphatidyl choline, cholesterol, anionic lipid(s) and cationic polymer
WO2005014791A2 (en) 2003-08-08 2005-02-17 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2004274957B2 (en) 2003-09-19 2009-02-05 Sangamo Therapeutics, Inc. Engineered zinc finger proteins for regulation of gene expression
US7534775B2 (en) 2004-04-08 2009-05-19 Sangamo Biosciences, Inc. Methods and compositions for modulating cardiac contractility
EP1750673B1 (en) 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2006033859A2 (en) 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
EP1799825B1 (en) 2004-10-05 2011-06-29 The California Institute of Technology Aptamer regulated nucleic acids and uses thereof
CA2599004C (en) 2005-02-28 2015-05-26 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
JP5140579B2 (en) 2005-06-08 2013-02-06 カンジェーン コーポレイション Hyaluronan binding peptides that enhance host defense against pathogens
CA2615532C (en) 2005-07-26 2016-06-28 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
AU2006298844B2 (en) 2005-09-20 2012-01-12 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siRAN
NZ598088A (en) 2005-10-21 2013-09-27 Univ California C-kit oncogene mutations in melanoma
CA2631082C (en) 2005-11-23 2015-02-03 Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
CA2632331C (en) 2005-12-22 2015-02-10 Vib Vzw Molecules with a beta-aggregating region and their use in inducing protein aggregation
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
DE602007005634D1 (en) 2006-05-25 2010-05-12 Sangamo Biosciences Inc Variant foki-splitting halves-domains
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
JP5770471B2 (en) 2007-07-12 2015-08-26 サンガモ バイオサイエンシーズ, インコーポレイテッド alpha-1,6-fucosyltransferase (FUT8) methods and compositions for inactivating gene expression
US8367815B2 (en) 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8865667B2 (en) 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US9029524B2 (en) 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
SG10201408162PA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
AU2009213147A1 (en) 2008-02-11 2009-08-20 Rxi Pharmaceuticals Corp. Modified RNAi polynucleotides and uses thereof
KR101794638B1 (en) 2008-06-10 2017-12-04 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for generation of bax- and bak-deficient cell lines
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP2313515B1 (en) 2008-08-22 2015-03-04 Sangamo BioSciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
WO2010065123A1 (en) 2008-12-04 2010-06-10 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US8551945B2 (en) 2009-02-04 2013-10-08 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
AU2010235161B2 (en) 2009-04-09 2015-01-22 Sangamo Therapeutics, Inc. Targeted integration into stem cells
EP2443155B1 (en) 2009-06-15 2017-03-29 Valerion Therapeutics, LLC Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1 (mtm1) polypeptides
WO2011016840A2 (en) 2009-07-28 2011-02-10 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
ES2550202T3 (en) 2009-08-03 2015-11-05 Recombinetics, Inc. Methods and compositions for targeted gene modification
CA2775747A1 (en) 2009-10-07 2011-04-14 Sanford Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
NZ601247A (en) 2010-01-22 2014-10-31 Dow Agrosciences Llc Targeted genomic alteration
WO2011097036A1 (en) 2010-02-08 2011-08-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
CA2788850C (en) 2010-02-09 2019-06-25 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
CN103108642B (en) 2010-03-24 2015-09-23 雷克西制药公司 rna interference with skin fibrosis symptoms in
CN103200945B (en) 2010-03-24 2016-07-06 雷克西制药公司 rna interference in ocular symptoms
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9057057B2 (en) 2010-07-27 2015-06-16 The Johns Hopkins University Obligate heterodimer variants of foki cleavage domain
WO2012024233A2 (en) 2010-08-14 2012-02-23 The Regents Of The University Of California Zwitterionic lipids
US9566352B2 (en) 2010-09-27 2017-02-14 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
EP2632939A4 (en) 2010-10-25 2014-05-14 Academia Sinica Taiwan Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
JP6214530B2 (en) 2011-07-15 2017-10-18 ザ ジェネラル ホスピタル コーポレイション Method of assembling a transcriptional activator-like effectors
WO2013044008A2 (en) 2011-09-21 2013-03-28 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
CA2865011A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3444342A1 (en) 2012-07-11 2019-02-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
EP2872154B1 (en) 2012-07-11 2017-05-31 Sangamo BioSciences, Inc. Methods and compositions for delivery of biologics
EA201590167A1 (en) 2012-08-29 2015-11-30 Сангамо Байосаенсез, Инк. Methods and compositions for the treatment of genetic disease
JP6401704B2 (en) 2012-10-10 2018-10-10 サンガモ セラピューティクス, インコーポレイテッド Compounds and their use to modify T cell
WO2014059255A1 (en) 2012-10-12 2014-04-17 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
EP2922529B1 (en) 2012-11-20 2019-03-13 Spectrum Pharmaceuticals, Inc. Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
AU2014281031A1 (en) 2013-06-17 2016-01-21 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105658796A (en) 2012-12-12 2016-06-08 布罗德研究所有限公司 CRISPR/CAS component systems, methods and compositions for sequence manipulation
WO2014204728A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
JP2016501531A (en) 2012-12-12 2016-01-21 ザ・ブロード・インスティテュート・インコーポレイテッド Delivery of array operations and systems for therapeutic applications, the methods and compositions, Engineering and Optimization
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP2784162B1 (en) 2012-12-12 2015-04-08 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
KR20150105633A (en) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 Engineering of systems, methods and optimized guide compositions for sequence manipulation
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
WO2014093635A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US10017581B2 (en) 2013-02-20 2018-07-10 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
CA2913234A1 (en) 2013-05-22 2014-11-27 Northwestern University Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
CA2926094A1 (en) 2013-10-17 2015-04-23 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US20160296605A1 (en) 2013-11-11 2016-10-13 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
EP3492593A1 (en) 2013-11-13 2019-06-05 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
AU2014361826A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using particle delivery components
RU2016128077A3 (en) 2013-12-12 2018-12-06
JP2017532001A (en) 2013-12-12 2017-11-02 ザ・ブロード・インスティテュート・インコーポレイテッド Systems for sequence manipulation by optimization CRISPR-Cas system, the methods and compositions
US10066241B2 (en) 2014-05-30 2018-09-04 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
KR20160013824A (en) 2014-07-28 2016-02-05 에스케이이노베이션 주식회사 Novel Isoprene Synthase and Method of Preparing Isoprene Using Thereof
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
KR20190008998A (en) 2015-01-28 2019-01-25 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 Crispr hybrid dna/rna polynucleotides and methods of use
AU2016243052A1 (en) 2015-04-03 2017-10-19 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
EP3298134A2 (en) 2015-05-16 2018-03-28 Genzyme Corporation Gene editing of deep intronic mutations
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205764A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
EP3118216A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Cellular growth and proliferation promoting peptides, and uses thereof
EP3118215A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Anti-inflammatory peptides, and uses thereof
EP3117831A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Peptides for use in promoting transport of glucose into skeletal muscle
EP3117830A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Antibacterial peptides, and uses thereof
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR20180133374A (en) 2015-10-22 2018-12-14 더 브로드 인스티튜트, 인코퍼레이티드 Type VI-B CRISPR Enzymes and Systems
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017184786A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Cpf1 complexes with reduced indel activity
EP3445848A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3026110A1 (en) 2016-04-19 2017-11-02 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3028158A1 (en) 2016-06-17 2017-12-21 The Broad Institute, Inc. Type vi crispr orthologs and systems
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
AU2017295898A1 (en) 2016-07-15 2019-02-21 Salk Institute For Biological Studies Methods and compositions for genome editing in non-dividing cells
WO2018014936A1 (en) 2016-07-18 2018-01-25 Nuritas Limited Topical compositions
CN109562153A (en) 2016-08-07 2019-04-02 诺华股份有限公司 The immunization method that mRNA is mediated
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
SG11201903282TA (en) 2016-10-13 2019-05-30 Juno Therapeutics Inc Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US10011848B2 (en) 2016-11-09 2018-07-03 City University Of Hong Kong System and method for delivery of substance into mammalian cells
CA3045323A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
EP3329905A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
WO2018104346A1 (en) 2016-12-05 2018-06-14 Nuritas Limited Compositions comprising peptide wkdeagkplvk
CA3046199A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
WO2018119060A1 (en) 2016-12-20 2018-06-28 Bristol-Myers Squibb Company Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
WO2018187688A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
WO2018208910A1 (en) 2017-05-09 2018-11-15 The Broad Institute Inc. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
WO2018229521A1 (en) 2017-06-16 2018-12-20 Oslo Universitetssykehus Hf Improved gene editing
WO2018234370A1 (en) 2017-06-20 2018-12-27 Institut Curie Immune cells defective for suv39h1
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019075292A1 (en) 2017-10-12 2019-04-18 Massachusetts Institute Of Technology Prostate cancer protease nanosensors and uses thereof
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019100023A1 (en) 2017-11-17 2019-05-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136456A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators

Also Published As

Publication number Publication date
WO1991017424A1 (en) 1991-11-14

Similar Documents

Publication Publication Date Title
AU664807B2 (en) Drug delivery system
AU678411B2 (en) Cannula pumps for temporary cardiac support
AU676753B2 (en) Drug delivery system
AU684088B2 (en) Novel therapeutic drug delivery systems
AU652071B2 (en) In vivo delivery of active factors by co-cultured cell implants
AU632539B2 (en) Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
AU633959B2 (en) Pharmaceutical formulations
AU636744B2 (en) Iontophoretic delivery device
AU647798B2 (en) Iontophoretic delivery device
AU669147B2 (en) Non-woven fabric material comprising hyaluronic acid derivatives
GB2273660B (en) Drug delivery arrangement
AU694677B2 (en) Pharmaceutical formulations of highly lipophilic camptothecin derivatives
AU619328B2 (en) Cytotoxic drug conjugates
AU658845B2 (en) Medical drug formulation and delivery system
AU653026B2 (en) Physiologically active polypeptide-containing pharmaceutical composition
AU630144B2 (en) Osmotically dependent vesicles
AU660627B2 (en) Functionally active selectin-derived peptide for GMP-140
AU654277B2 (en) Controlled release drug formulation
AU652135B2 (en) Two-part device for the controlled delivery of an active ingredient
AU678781B2 (en) Ultrasonic transdermal drug delivery system
EP0475160B8 (en) Preparation for drug application in minute droplet form
AU649439B2 (en) Activity controlled electrotransport drug delivery device
AU656924B2 (en) Biphasic release formulations for lipophilic drugs
AU5402296A (en) Pharmaceutical composition for transdermic administration
AU635133B2 (en) Pharmaceutical formulations